The collaboration allows HGS to develop 4-Antibody’s proprietary in vitro Retrocyte Display technology (Retroviral B lymphocyte Display) to discover sources for antibody drug candidates.
Retrocyte Display creates therapeutic antibody drug candidates using a flow cytometry by integrating full-length IgG format human antibody libraries expressed in mammalian B cells.
4-Antibody CEO Robert Burns said they are delighted to announce their second collaboration with a pharmaceutical partner.